Why the study?
Doxorubicin-induced cardiotoxicity involves complex molecular mechanisms with a central role of p38 MAPK signaling that require comprehensive review.
Design
Review article summarizing molecular mechanisms and therapeutic insights
p38 MAPK inhibition merits preclinical testing to limit DOX cardiotoxicity; leaves open clinical translation in oncology patients.
Doxorubicin (DOX) is a widely used anticancer agent, but its use carries the risk of cardiotoxicity. The underlying mechanisms of DOX-induced cardiac injury involve multiple interconnected processes, including oxidative stress, inflammatory activation, apoptosis, dysregulation of metal ion homeostasis, mitochondrial dysfunction, and impaired autophagy. The p38 mitogen-activated protein kinase (p38 MAPK) pathway functions as a stress-response central hub that integrates these signals and orchestrates downstream cellular outcomes via phosphorylation-dependent signaling cascades. This review summarizes current evidence on the molecular mechanisms of DOX-induced cardiotoxicity (DIC), with a focus on the pivotal role of the p38 MAPK pathway. We further discuss natural compounds that mitigate DIC via modulation of p38 MAPK signaling and examine emerging evidence on sex-specific cardioprotective effects mediated by distinct p38 MAPK isoforms. In addition, we briefly discuss the role of DOX nanoformulations in reducing cardiotoxicity, offering new insights into the mitigation of DIC.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: